Tourette's Disorder

The need to develop strategies for the clinical management of TS and associated disorders is high. This unmet medical need remains large as accompanying symptoms and discomforts due to tics have a profound impact on the overall functioning and quality of lift of TS patients individually and constitute a significant burden to society more broadly. Gemlapodect is an investigational selective PDE10A inhibitor with the potential to provide therapeutic benefit for TS, specifically for the treatment of tics associated with TS.

While there is no cure for Tourette Syndrome, currently available treatments are focused on controlling tics that interfere with everyday activities and functioning. The need for new TS therapies is high, as the accompanying symptoms and discomforts associated with tics have a profound impact on the functioning and quality of life of patients and their families; more broadly, TS negatively impacts societal burden, carrying an increased risk of depression and substance abuse.